This website uses cookies. By using the site you are agreeing to our Privacy Policy.

Top of the page.
Skip the menu to main contents.
Move to main menu.
Skip to main contents.

Main menu starts here.
Skip the main menu to current location in your website.

Current location in your website.
Skip to main contents.

What's New


The information in news releases is current at the time of the release. Note that the information shown here may not be latest information (termination of production or sales, changes to specifications or pricing, organizational or contact address changes, etc.), and may be subject to change without prior notice.

Toyama Chemical Co., Ltd. has concluded a research and development collaboration and license agreement on program for generation of innovative antibacterial agent with GlaxoSmithKline
September 8, 2004

September 8, 2004, Tokyo; Toyama Chemical Co., Ltd. (President and CEO: Katsuhiko Nakano) announced today that it has entered into a research and development collaboration and license agreement with respect to creating novel antibacterial agents from GSK's compound library.

Overview of the agreement

GSK will screen compounds within its compound bank against certain targets owned by GSK. Toyama Chemical will optimize hit compounds from GSK's screening. Toyama Chemical will develop and commercialize the optimized compounds in Japan. Toyama Chemical has the option to co-commercialize compounds in China and South Korea.

Toyama Chemical will receive milestone payments based on certain development milestones being reached by GSK. Toyama Chemical will receive royalties from GSK based on the net sales of the product worldwide except Japan, China and South Korea. Toyama Chemical will pay royalties to GSK based on the net sales of the product in Japan.

Research and development collaboration

GSK will collaborate with Toyama to expand and complement GSK's internal anti-microbial drug discovery capabilities with respect to optimizing novel compounds. Toyama Chemical has developed excellent novel antibacterial agents, which were supported by its predominant synthetic capability. Toyama Chemical will utilize its expertise in R&D in the strategic alliance with GSK, and seeks to attract other collaborators in order to gain a global presence.

Toyama Chemical Co., Ltd. constantly strives to supply the world with innovative treatment methods for infectious diseases. In collaboration with GSK, Toyama Chemical aims to develop excellent antibacterial agents.

Footer starts here.

Pages ends here.
Move to top of the page.